NCT01578967 2021-12-07
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase NA Completed
Clinical Trials
3 trialsNCT01841021 2017-01-19
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Terminated
NCT01671813 2013-07-25
Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Withdrawn